Fredag 7 November | 10:57:09 Europe / Stockholm

Kalender

Est. tid*
2026-02-05 08:30 Bokslutskommuniké 2025
2025-11-13 08:30 Kvartalsrapport 2025-Q3
2025-08-21 - Kvartalsrapport 2025-Q2
2025-05-30 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2025-05-28 - Årsstämma
2025-05-15 - Kvartalsrapport 2025-Q1
2025-02-06 - Bokslutskommuniké 2024
2024-11-14 - Kvartalsrapport 2024-Q3
2024-10-30 - Split EXPRS2 40:1
2024-08-15 - Kvartalsrapport 2024-Q2
2024-06-07 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2024-06-05 - Årsstämma
2024-05-16 - Kvartalsrapport 2024-Q1
2024-02-08 - Bokslutskommuniké 2023
2023-11-16 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-25 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2023-05-24 - Årsstämma
2023-05-16 - Kvartalsrapport 2023-Q1
2023-03-23 - Extra Bolagsstämma 2023
2023-02-09 - Bokslutskommuniké 2022
2022-11-17 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-31 - Kvartalsrapport 2022-Q1
2022-05-27 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2022-05-25 - Årsstämma
2022-02-24 - Bokslutskommuniké 2021
2021-11-18 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-27 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2021-05-26 - Årsstämma
2021-05-19 - Kvartalsrapport 2021-Q1
2021-02-25 - Bokslutskommuniké 2020
2020-11-19 - Kvartalsrapport 2020-Q3
2020-09-23 - Extra Bolagsstämma 2020
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-27 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2020-05-26 - Årsstämma
2020-05-20 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-24 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2019-05-23 - Årsstämma
2019-05-16 - Kvartalsrapport 2019-Q1
2019-02-28 - Bokslutskommuniké 2018
2018-11-22 - Kvartalsrapport 2018-Q3
2018-08-24 - Kvartalsrapport 2018-Q2
2018-05-25 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2018-05-24 - Årsstämma
2018-05-17 - Kvartalsrapport 2018-Q1
2018-02-07 - Bokslutskommuniké 2017
2017-11-30 - Kvartalsrapport 2017-Q3
2017-08-31 - Kvartalsrapport 2017-Q2
2017-06-01 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2017-05-31 - Årsstämma
2017-05-24 - Kvartalsrapport 2017-Q1
2017-04-19 - Extra Bolagsstämma 2017
2017-02-28 - Bokslutskommuniké 2016
2016-11-08 - Kvartalsrapport 2016-Q3
2016-08-31 - Kvartalsrapport 2016-Q2

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
ExpreS2ion är ett bioteknikbolag fokuserat på utveckling av vacciner. Bolagets mål att bidra till hälso- och sjukvården genom att utveckla vacciner ämnade att stödja sjukdomsförebyggande och förbättra livskvaliteten globalt. ExpreS2ion använder sin ExpreS2™-teknologiplattform, som har validerats i kliniska fas III-studier, för utveckling och produktion av vaccinkomponenter. Bland pågående projekt utvecklar bolaget ES2B-C001, ett HER2-cVLP bröstcancervaccin som genomgår kliniska fas I-prövningar.
2025-09-12 21:02:31
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, RUSSIA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, 12 September 2025 - ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") announces that the exercise price for the warrants of series TO 11 has been determined to SEK 14.65 and that the exercise period starts on 18 September 2025.

CEO Bent Frandsen comments:
“The warrant exercise period provides ExpreS2ion with an important opportunity to strengthen our financial position as we advance our HER2 breast cancer immunotherapy through Phase I. The TO 11 warrants represent a way for our shareholders to further engage in ExpreS2ion’s development journey. Their support is especially important as we progress our breast cancer immunotherapy program, where upcoming clinical milestones may represent significant value inflection points for the company.”

ExpreS2ion completed a rights issue of units during the third quarter of 2024. Within the scope of the rights issue, ExpreS2ion issued a total of 32,221,672 warrants of series TO 11, of which 30,046,672 warrants of series TO 11 were issued as a result of the rights issue, and an additional 2,175,000 warrants of series TO 11 were issued to rights issue guarantors who chose to receive guarantee compensation in units.

Prior to recalculation of the warrants of series TO 11, one (1) warrant of series TO 11 gave the owner the right to subscribe for one (1) new share in the Company. Following the recalculation of the warrants, which is explained in more detail below, forty (40) warrants of series TO 11 gives the owner the right to subscribe for one (1) new share in the Company. The exercise price for the warrants of series TO 11 was defined as 70 percent of the volume-weighted average price in the Company's share on Nasdaq First North Growth Market during the measurement period, from 1 September 2025 to 12 September 2025, but not less than the share's quota value (SEK 4.444444) and not more than SEK 70 (previously SEK 1.75) per share (following recalculation). During the measurement period, the volume-weighted average price in the Company's share was approximately SEK 20.94, therefore the exercise price for the warrants of series TO 11 has been set to SEK 14.65. The exercise period for warrants of series TO 11 runs from 18 September 2025 up to and including 2 October 2025.

If the warrants of series TO 11 are fully exercised, the Company will receive gross proceeds of approximately SEK 11.8 million before issue costs, which are expected to amount to approximately SEK 0.3 million. The expected net proceeds of approximately SEK 11.5 million will be used as follows (in the following order of priority):

  1. Advance ES2B-C001 — complete Phase Ia through safety and maximum tolerated dose readout, with potential immunogenicity and early efficacy signals, representing a key value inflection point (approx. 65%)

  2. Pipeline and platform — working capital to expand pipeline and strengthen Phase III validated platform (approx. 20%)

  3. Scale the contract research business — grow service revenues and validate the platform with external customers (approx. 10%)

  4. Co-finance grant projects — limited co-financing of externally funded projects with future pipeline/licensing opportunities (approx. 5%)

For the warrants to not expire without value, it is required that the holder actively subscribes for new shares no later than on 2 October 2025 or sell the warrants no later than on 30 September 2025. Please observe that certain nominees might close their applications earlier than on 2 October 2025.

Full terms and conditions regarding the warrants of series TO 11 and information about the Company is available in the prospectus which was approved by the Swedish Financial Supervisory Authority (the "SFSA") and published by the Company on 5 June 2024. The prospectus is available on the Company's investor relations website investor.expres2ionbio.com, as well as the SFSA's website www.fi.se.

Recalculation of outstanding warrants of series TO 11
Due to a reverse share split in the Company, a recalculation has been made in accordance with the terms and conditions of the Company's warrants of series TO 11 regarding the subscription price and the number of shares that each warrant entitles to subscribe for. Other terms and conditions for the warrants of series TO 11 have remained unchanged. The total number of outstanding warrants have not changed as a result of the reverse share split and the recalculation.

After the recalculation, the subscription price per share when exercising warrants of series TO 11 shall correspond to 70 percent of the volume-weighted average price of the Company's share on Nasdaq First North Growth Market during the period from and including 1 September 2025 until and including 12 September 2025, however, not less than the share's quota value (SEK 4.444444) and not more than SEK 70 (previously SEK 1.75). The new number of shares that each warrant entitles to subscribe for amounts to 0.025 shares (previously one (1) share) after the recalculation. Subscription cannot be made by part of a share, which means that forty (40) warrants of series TO 11 will be required to subscribe for one (1) new share in the Company.

Summarised terms for the warrants of series TO 11

  • Exercise period: 18 September 2025 – 2 October 2025.

  • Issue size: 32,221,672 warrants of series TO 11, which entitles to subscription of 805,541 shares. If all the warrants are exercised, the Company will receive approximately SEK 11.8 million before issue costs.

  • Forty (40) warrants of series TO 11 will be required to subscribe for one (1) new share in the Company.

  • Exercise price: SEK 14.65 per share.

  • Last day for trading warrants of series TO 11: 30 September 2025.

  • Effect on share capital and dilution: If all warrants are exercised the share capital will increase with SEK 3,580,182.228718. If all warrants of series TO 11 are exercised the number of shares will increase with 805,541 shares. The dilution if all warrants of series TO 11 are exercised amounts to approximately 23.3 percent of the number of shares and votes in the Company.

Note that the warrants not exercised on 2 October 2025 at the latest or sold no later than on 30 September 2025, will expire without value. For the warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants.

How warrants are exercised
Nominee-registered warrants (Custody account) - Subscription and payment by the exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information. This should be done well before 2 October 2025, as different nominees have different processing times.

Directly-registered warrants (Securities account) - No issue report nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form.

The warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.

Additional information can be found in the TO 11 warrant brochure, which will be made available in the Rights Issue 2024 (https://investor.expres2ionbio.com/rights-issue-2024/) section of the ExpreS2ion investor website, under IPO and Rights Issues, at the start of the exercise period.

The application form, including instructions for payment, will be available at ExpreS2ion's investor relations website, investor.expreS2ionbio.com and Vator Securities website (www.vatorsecurities.se).

Advisors
Vator Securities act as financial advisor and issuing agent to the Company in connection with the transaction. Advokatfirman Schjødt is the Company's legal advisor in connection with the transaction.

Certified Adviser
Svensk Kapitalmarknadsgranskning AB